Photo of Dong  Chen, MD, PhD

Dong Chen, MD, PhD

Assistant Professor, Pathology and Laboratory Medicine
Director, Hematopathology
NPI Number:
1356721781
Academic Office Location:
Pathology and Laboratory Medicine
UConn Health
263 Farmington Avenue
Farmington, CT 06030
Fax: 860-679-4334
Email: dochen@uchc.edu
Website(s):

Pathology and Laboratory Medicine

Education
DegreeInstitutionMajor
MDShanghai Medical College of Fundan UniversityMedicine
PhDVirginia Commonwealth UniversityPathology/Experimental Pathology

Post-Graduate Training
TrainingInstitutionSpecialty
ResidencyUniversity of Missouri Health CareAnatomic and Clinical Pathology
FellowshipBarnes-Jewish Hospital/Washington UniversityPathology/Selective Surgical Pathology
FellowshipUniversity of Texas Southwestern Medical CenterHematopathology

Awards
Name of Award/HonorAwarding Organization
TSP 100th Annual Abstract Competition: Investigative Posters 3rd Place, "Emergence of CD19(-) B-lymphoblastic Leukemia in CD19-Targeting Immunotherapy and L1LRB1 as a Novel Diagnostic B-cell Marker"Texas Society of Pathology
Honor SocietyPhi Kappa Phi
  • Hematopathology
  • Flow Cytometry
  • Novel Biomarker
  • Myeloproliferative Neoplasm

Journal Articles

Case Reports

Reviews

Title or AbstractTypeSponsor/EventDate/YearLocation
A comparative analysis of TP53 mutation sites in blast phase myeloproliferative neoplasm and acute myeloid leukemiaPosterISLH2024Nantes, France
Prostate cancer with diffuse bone marrow carcinomatosis.PosterNNECOS2023Northern New England Clinical Oncology Society
VEXAS syndrome.PosterNNECOS2023Northern New England Clinical Oncology Society
Clinical, pathologic and genomic comparison of myeloproliferative neoplasm in blast phase (MPN-BP) with AML with unfavorable cytogenetics.PosterUSCAP2022USCAP
Clinicopathologic features of relapsed CD19(-) B-ALL in CD19-targeted immunotherapy: insights into mechanism of relapse and LILRB1 as a novel B-cell marker for CD19(-) B lymphoblasts.PosterUSCAP2021USCAP
Emergence of CD19(-) B-lymphoblastic leukemia in CD19-targeting immunotherapy and LILRB1 as a novel diagnostic B-cell markerPosterTexas Society of Pathology2021